The weight loss drug market is experiencing explosive growth, with the global anti-obesity medication market expected to expand from $19.6 billion in 2025 to $104.9 billion by 2035, representing an 18.3% annual growth rate. This dramatic shift reflects not just increased demand for obesity treatment, but a fundamental transformation in how these medications are being developed, delivered, and prescribed.

The surge in popularity of GLP-1 receptor agonists like semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) has created unprecedented market momentum. In England, Wales, and Scotland alone, an estimated 1.6 million adults used weight loss drugs in the past year, a figure so significant that major supermarkets have begun launching food ranges specifically targeting users of these medications.

What's Driving the Shift Away From Injectable Medications?

One of the most significant changes on the horizon is the move toward oral formulations of weight loss drugs. In December 2025, the U.S. Food and Drug Administration (FDA) approved the first oral GLP-1 medication, Wegovy pill, designed to reduce excess body weight and maintain weight reduction long term while reducing the risk of major adverse cardiovascular events. This approval is opening doors for other oral weight loss medications currently in late-stage development.

Patient preference strongly supports this shift. In a survey of over 1,000 adults living with obesity, 71% said they would prefer a daily pill over a weekly injection when taking a prescription weight loss medication. Beyond convenience, 73% of respondents reported openness to non-injectable and non-GLP-1 options after discontinuing GLP-1 treatment, suggesting patients understand that obesity management requires long-term, flexible approaches.

"Any shift that increases access and affordability for people living with obesity is positive. Cost remains one of the biggest barriers to continuity of care," said Dr. Michael Kyle, Chief Medical Officer at Currax Pharmaceuticals.

Dr. Michael Kyle, Chief Medical Officer at Currax Pharmaceuticals

The affordability issue has gained political attention as well. In November 2025, U.S. President Donald Trump announced deals with major pharmaceutical manufacturers Eli Lilly and Novo Nordisk aimed at lowering the cost of popular weight loss drugs, recognizing that expense remains a significant barrier to treatment access.

How Are Combination Therapies Improving Weight Loss Results?

• Enhanced Weight Loss: OrsoBio's oral mitochondrial protonophore TLC-6740, when combined with tirzepatide, achieved mean weight loss of 13.3% at week 24, compared with 8.8% with tirzepatide alone in a Phase Ib/IIa trial involving multiple participants.
• Improved Metabolic Health: The combination therapy produced significant improvements in insulin sensitivity, liver biochemistry, adiponectin levels, and hsCRP (a marker of inflammation), addressing multiple aspects of metabolic dysfunction beyond weight alone.
• Better Body Composition: An MRI substudy demonstrated meaningful reductions in liver fat and total, visceral, and skeletal muscle adiposity, with no adverse impact on lean muscle mass, a critical concern with weight loss medications.
• Additive Effects: Antag Therapeutics' novel GIPR antagonist, when combined with cagrilintide and liraglutide, demonstrated additive effects on weight loss, body composition, insulin sensitivity, and cardiovascular risk biomarkers without increasing gastrointestinal side effects.

These combination approaches address one of the major challenges with current weight loss medications: managing side effects while maximizing therapeutic benefit. By pairing GLP-1 drugs with complementary treatments, pharmaceutical companies are working to reduce gastrointestinal distress and muscle loss, two significant concerns that can limit treatment adherence.

"The potential for AT7687 to not only enhance weight loss but also have strong additive effect on both healthier body composition and insulin sensitivity, without increasing the tolerability burden, is especially compelling," stated Jörg Möller, Chief Executive Officer of Antag Therapeutics.

Jörg Möller, Chief Executive Officer of Antag Therapeutics

Why Is Precision Medicine Becoming Central to Obesity Treatment?

Beyond new drug formulations and combinations, the obesity treatment landscape is shifting toward precision diagnostics and personalized approaches. Rather than a "one-size-fits-all" strategy, companies are developing AI-enabled diagnostics to identify subtypes of obesity and match patients with the therapies most likely to work for their specific biology.

This precision approach has meaningful implications. Some patients may avoid exposure to medications that are less effective for their particular metabolic profile, while others gain access to treatments better matched to their needs. Over time, this more targeted strategy can lead to better outcomes and more sustainable medication use, rather than simply increasing or decreasing total prescriptions.

The shift toward precision medicine also reflects a broader reorientation in how obesity is understood and treated. Experts emphasize that obesity is a chronic metabolic disease requiring long-term management and clinical guidance, not a cosmetic concern or a one-time quick fix. This distinction matters for how medications are developed, marketed, and prescribed.

"Obesity is a chronic metabolic disease, not a cosmetic goal. Insights like AI-enabled diagnostics that identify subtypes of disease are designed to ensure people receive therapies that are the most likely to work for them," explained Mark Bagnall, Chief Executive Officer of Phenomix Sciences.

Mark Bagnall, Chief Executive Officer of Phenomix Sciences

What About Patients Who Don't Respond to GLP-1 Drugs?

While GLP-1 receptor agonists have dominated recent headlines, the expanding market is creating renewed interest in alternative oral medications for patients who don't respond adequately to these drugs or who experience intolerable side effects. Qsymia, a first-generation oral obesity medication, has demonstrated effectiveness in a significant subset of patients, with research showing that many individuals lose over 15% of their body weight on this medication.

As oral GLP-1 formulations become standard treatment options, experts anticipate a resurgence of interest in all oral weight loss medications, providing clinicians with more tools to match the right therapy to the right patient. This diversity of options supports the goal of helping more people stay engaged in long-term obesity management by offering choices that align with individual preferences and medical needs.

The regulatory environment is also evolving to support safer, more targeted use of these medications. In positive news for manufacturers, the FDA has removed the requirement for a "suicidal behavior and ideation" warning from product labels for weight loss drugs, reflecting updated safety data. However, ongoing monitoring of muscle loss and gastrointestinal side effects remains a priority as these medications are used more widely.

Key Takeaways: What This Means for Weight Loss Treatment

The obesity drug market is entering a new era characterized by greater choice, improved accessibility, and more personalized approaches to treatment. Oral formulations are expanding access to patients who prefer pills over injections. Combination therapies are enhancing weight loss results while reducing side effects. Precision diagnostics are helping match patients with the most effective treatments for their biology. And a growing recognition that obesity is a chronic disease requiring long-term management is reshaping how these medications are prescribed and supported. As the market continues its projected growth toward $104.9 billion by 2035, patients living with obesity will have more options, better information, and stronger clinical support than ever before.